Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Clinical trial NCT02586155 · COMPLETED
Trial details
- NCT number
- NCT02586155
- Sponsor
- Resverlogix Corp
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-01
- Primary completion
- 2020-11-30
- Enrollment
- 2425
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.